Merck & Co.’s Winrevair Approved for Pulmonary Arterial Hypertension in Hainan
US-based giant Merck & Co., Inc. (NYSE: MRK) announced receiving approval from the Hainan Medical...
US-based giant Merck & Co., Inc. (NYSE: MRK) announced receiving approval from the Hainan Medical...
China-based rare disease specialist CANbridge Pharmaceuticals Inc. (HKG: 1228) announced that the first patient has...
Pfizer Inc. (NYSE: PFE) announced the implementation of its hemophilia therapy Hympavzi (marstacimab) in China’s...
In-Depth Analysis and Orientation Guide for Hainan’s Biomedical New Technology PolicyThe Hainan Provincial Health Commission,...
The Boao Airport Customs under Haikou Customs has released the first batch of 96 pieces...
The Hainan Boao Lecheng Pilot Zone Management Bureau announced the implementation of Baclofen Intrathecal Sintetica,...
French pharmaceutical giant Sanofi (NASDAQ: SNY) has announced that it has received marketing approval from...
The State Administration for Market Regulation (SAMR) in China has given its approval in principle...
The Hainan Boao Lecheng International Medical Tourism Pilot Zone, in collaboration with France’s major Sanofi’s...
French pharmaceutical company Servier’s Voranigo (vorasidenib), an isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor,...
In a joint effort to bolster healthcare services, China’s Ministry of Finance, National Health Commission...
Hainan’s disciplinary inspection committee has announced the expulsion of Li Jingquan, the former president of...
Hairstetics, an Israeli innovator in the non-absorbable polyamide hair transplant sector, has achieved a milestone...
Swiss pharmaceutical and diagnostics giant Roche (SWX: ROG) has received approval from the Hainan Medical...
Beijing has unveiled an ambitious plan to construct Bio-Park, a state-of-the-art international pharmaceutical innovation park...
ANI Pharmaceuticals’ Veregen, a topical ointment derived from green tea extract (catechins), has been implemented...
Shanghai Ruijin Hospital’s Hainan subsidiary has initiated a real-world study for Orserdu (elacestrant), a next-generation...
Jiangsu-based HOB Biotech Group Corp., Ltd (SHA: 688656) has announced that it has received clinical...
Eslicarbazepine, a voltage-gated sodium channel blocker, co-developed by Bial-Portela, Eisai, and Sumitomo Pharma, was first...
Tzield (teplizumab), recognized as the world’s first and only targeted therapy for delaying the onset...